Protocol Ledger

NCT07039162 · Phase II · RECRUITING

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Interventional Phase II clinical trial protocol NCT07039162 sponsored by Ming-Yu Lien in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-26 Enrollment: 45 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07039162
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07039162
Protocol FieldVerified Registry Value
NCT IdentifierNCT07039162
Consolidated Lead SponsorMing-Yu Lien
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment45 participants (ESTIMATED)
Registered Start Date2025-09-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07039162
Hospital Research SiteLocationSite Profile
Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->
Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->
China Medical University HospitalTaichung, TaiwanOpen Hospital Dossier ->
Taichung Veterans General HospitalTaichung, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI